tbuckley/cabot-search huggingface dataset:
Association Between Clinician Computer Use and Communication With Patients in Safety-Net Clinics
Authors: Neda Ratanawongsa, Jennifer L. Barton, Courtney R. Lyles, Michael Wu, Edward H. Yelin, Diana Martinez, Dean Schillinger
Journal: JAMA Internal Medicine (2015)

issue guidelines on the inclusion of women in clinical trials. 6 Given that KD is highly prevalent and may modify relevant parameters of some medications or procedures (eg, efficacy, safety, and pharmacokinetics), patients with KD should be included in cardiovascular trials in the absence of absolute contraindications.Investigators' goal should be to enroll a study population in which the prevalence and severity of KD match the prevalence and severity in the target population.Furthermore, investigators should consider stratifying treatment assignment based on kidney function to achieve balance and should report outcome and safety results stratified by level of baseline kidney function.What does widespread exclusion of patients with KD from cardiovascular trials mean for the practicing internist or nephrologist who must manage CVD in patients with KD? Unfortunately, the currently available randomized clinical trial data on the efficacy and safety of cardiovascular interventions in patients with KD is insufficient to make recommendations on the optimal approach for many therapies.This report underscores the need for greater inclusion of patients with KD in cardiovascular trials or the design of trials specifically focused on this population to better characterize the risks and benefits of cardiovascular interventions in this highly prevalent and prognostically important subgroup of patients.The number of randomized clinical trials within the field of nephrology is low, and the trials are of poor quality and are unlikely to provide adequate data on the treatment of CVD in patients with KD. 2 Extrapolation of trial results conducted in the general population to patients with KD may or may not be appropriate, and a deeper understanding of the barriers to including patients with KD in cardiovascular trials and the development of strategies to overcome them is urgently needed.
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
Authors: Mark W. Clemens, L. Jeffrey Medeiros, Charles E. Butler, Kelly K. Hunt, Michelle A. Fanale, Steven Horwitz, Dennis D. Weisenburger, Jun Liu, Elizabeth A. Morgan, Rashmi Kanagal-Shamanna, Vinita Parkash, Jing Ning, Aliyah R. Sohani, Judith A. Ferry, Neha Mehta-Shah, Ahmed Dogan, Hui Liu, Nora Thormann, Arianna Di Napoli, Stephen Lade, Jorge Piccolini, Ruben Reyes, Travis Williams, Colleen M. McCarthy, Summer E. Hanson, Loretta J. Nastoupil, Rakesh Gaur, Yasuhiro Oki, Ken H. Young, Roberto N. Miranda
Journal: Journal of Clinical Oncology (2015)

Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is a rare type of T-cell lymphoma that arises around breast implants. The optimal management of this disease has not been established. The goal of this study is to evaluate the efficacy of different therapies used in patients with BI-ALCL to determine an optimal treatment approach.In this study, we applied strict criteria to pathologic findings, assessed therapies used, and conducted a clinical follow-up of 87 patients with BI-ALCL, including 50 previously reported in the literature and 37 unreported. A Prentice, Williams, and Peterson model was used to assess the rate of events for each therapeutic intervention.The median and mean follow-up times were 45 and 30 months, respectively (range, 3 to 217 months). The median overall survival (OS) time after diagnosis of BI-ALCL was 13 years, and the OS rate was 93% and 89% at 3 and 5 years, respectively. Patients with lymphoma confined by the fibrous capsule surrounding the implant had better event-free survival (EFS) and OS than did patients with lymphoma that had spread beyond the capsule (P = .03). Patients who underwent a complete surgical excision that consisted of total capsulectomy with breast implant removal had better OS (P = .022) and EFS (P = .014) than did patients who received partial capsulectomy, systemic chemotherapy, or radiation therapy.Surgical management with complete surgical excision is essential to achieve optimal EFS in patients with BI-ALCL.
Synaptic plasticity model of therapeutic sleep deprivation in major depression
Authors: Elias Wolf, Marion Kuhn, Claus Normann, Florian Mainberger, Jonathan G. Maier, Sarah Maywald, Aliza Bredl, Stefan Klöppel, Knut Biber, Dietrich van Calker, Dieter Riemann, Annette Sterr, Christoph Nissen
Journal: Sleep Medicine Reviews (2015)
Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastasis
Authors: Pooja M Dhupkar, Ling Yu, Nancy Gordon, Eugenie S Kleinerman
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Osteosarcoma (OS) is a primary bone malignancy, commonly culminating into aggressive pulmonary metastasis. Despite chemotherapy advances, the 5-year survival of pulmonary metastatic OS remains 25-30%. Immunotherapy is one of the promising novel approaches to target minimal
Secretagogin is a novel marker for identification of neuroendocrine tumors.
Authors: Karin Birkenkamp-Demtroeder, Ludwig Wagner, Flemming Brandt Sørensen, Lone Bording Astrup, Wolfgang Gartner, Hans Scherübl, Bernhard Heine, Peer Christiansen, Torben Falck Ørntoft
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

5157 

Patients with carcinoid tumors are amenable to cure, if the tumor is detected before metastases occur. As liver metastases can already be present at a tumor size of 1-2 cm, the identification of new diagnostic markers may have a significant impact on disease management. Our previous microarray based studies identified secretagogin to be highly expressed in normal colon mucosa, compared to a low expression in adenocarcinomas. Secretagogin was previously identified in the brain and pancreas and represents an EF-hand calcium-binding protein related to calbindin D-28K and calretinin, which is thought to be involved in transmitting calcium signals in the control of cell proliferation. The aim of this study was to analyze the differential expression of secretagogin in normal mucosa, adenocarcinomas, and neuroendocrine tumors using Western blotting, immunohistochemistry, co-localization by immunofluorescence microscopy as well as ELISA analysis on plasma samples. Western blot analysis showed a single 32kDa secretagogin band in samples from normal colon mucosa. Immunohistochemical analyses on formalin-fixed paraffin-embedded (FFPE) specimen showed that secretagogin is exclusively expressed in neuroendocrine cells and nerve cells of normal mucosa of the digestive tract. Tissues adjacent to benign hyperplasic polyps and adenomas showed a decreased number of secretagogin-expressing neuroendocrine cells. Immunfluorescence studies on FFPE sections co-localized Secretagogin with common neuroendocrine markers (Chromogranin A, Neuron specific enolase and synaptophysin) in single neuroendocrine cells located in crypts of normal mucosa as well as in tumor cells in carcinoids. Secretagogin protein was localized in the cytosol and the nucleus of 19 well-differentiated neuroendocrine carcinoids and 4 carcinoid metastases. Furthermore, Secretagogin was strongly up-regulated in other neuroendocrine tumors from the lung, pancreas and adrenal gland. Absorbance based ELISA analyses on plasma samples from 17 carcinoids and 7 adenocarcinoids (composite carcinoids or goblet cell carcinoid) showed measurable elevated secretagogin levels in the range 8-1800 pg/ml in five of eight samples from carcinoid patients with distant metastasis. Combined immunohistochemical analysis of secretagogin and FKBP65 (FK506 binding protein 65), a protein we had recently identified to be de novo synthesized in adenocarcinomas, distinguished well-differentiated carcinoids, adenocarcinoids and undifferentiated carcinomas. In conclusion, secretagogin resembles a novel marker for identification of cells with neuroendocrine differentiation in neuroendocrine tumors.
Sequelae Following Postnatally Acquired Cytomegalovirus Infection in Very Low-Birth-Weight Neonates
Authors: David W. Kimberlin
Journal: JAMA Pediatrics (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
WITHDRAWN: Multilayer assembly of liposomal nanoparticles to enhance the systemic delivery of multiple anticancer drugs
Authors: Ju Yeon Choi, Ruttala Hima Bindu, Ramasamya Thiruganesh, Yong Joo Choi, Toe Kyung Go, Dong Shik Kim, Han-Gon Choi, Jee-Heon Jeong, Chul Soon Yong, Jong Oh Kim
Journal: Asian Journal of Pharmaceutical Sciences (2015)

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
The incidence of concussion in youth sports: a systematic review and meta-analysis
Authors: Ted Pfister, Ken Pfister, Brent Hagel, William A Ghali, Paul E Ronksley
Journal: British Journal of Sports Medicine (2015)

Objective To conduct a comprehensive systematic review and meta-analysis of studies assessing the incidence of concussion in youth athletes. Specifically, we estimate the overall risk of concussion in youth sports and compare sport-specific estimates of concussion risk. Design Systemic review and meta-analysis. Data sources A search of Medline, Embase (1980 through September 2014), and SportDiscus (1985 through September 2014) supplemented by manual searches of bibliographies and conference proceedings. Inclusion criteria We included studies if they met the inclusion criteria of study design (prospective cohort study), relevant sports identified from the literature (eg, American football, rugby, hockey, lacrosse, soccer/football, basketball, baseball, softball, wrestling, field hockey, track, taekwondo, volleyball and cheerleading), population (males and females ≤18 years old), and outcome (concussion). Results Of the 698 studies reviewed for eligibility, 23 articles were accepted for systematic review and 13 of which were included in a meta-analysis. Random effects models were used to pool overall and sport-specific concussion incidence rates per 1000 athlete exposures (AEs). The overall risk of concussion was estimated at 0.23 (95% CI 0.19 to 0.28). The three sports with the highest incidence rates were rugby, hockey and American football at 4.18, 1.20 and 0.53, respectively. Lowest incidence rates per 1000 AEs occurred in volleyball, baseball and cheerleading at 0.03, 0.06 and 0.07, respectively. Quality of the included studies varied, with the majority of studies not reporting age and gender-specific incidence rates or an operational definition for concussion. Conclusions There are striking differences in the rates of incident youth concussion across 12 sports. This systematic review and meta-analysis can serve as the current sport-specific baseline risk of concussion among youth athletes.
Age-Related Decline of Perforin Expression in Human Cytotoxic T Lymphocytes and Natural Killer Cells
Authors: Daniel Rukavina, Gordana Laskarin, Gordana Rubesa, Natasa Strbo, Ivica Bedenicki, Darko Manestar, Mario Glavas, Stephen E. Christmas, Eckhard R. Podack
Journal: Blood (1998)
Role of Intraspinal Analgesia in Terminal Pediatric Malignancy
Authors: J.M. Saroyan, W.S. Schechter, M.E. Tresgallo, L. Granowetter
Journal: Journal of Clinical Oncology (2005)

HERE’S THE CASE A 15-year-old girl from the Caribbean presented with high-grade pleomorphic osteogenic sarcoma of her distal right femur and multiple bilateral pulmonary nodules. After two courses of high-dose methotrexate, cisplatin, and doxorubicin, a limb-sparing procedure was performed. The margins were negative for tumor, and the tumor necrosis was approximately 75%. Chemotherapy continued, bilateral thoracotomies were performed, and ifosfamide and etoposide were added to the patient’s regimen. Imaging studies showed no evidence of disease, and therapy was continued in her home country. She returned with a left-sided foot drop
Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT).
Authors: Eric P. Winer, Sara Tolaney, Hovav Nechushtan, Raanan Berger, Razelle Kurzrock, Ilan-Gil Ron, Patrick Schoffski, Ahmad Awada, Christopher A. Yasenchak, Howard A. Burris, David A. Ramies, Teresa Rafferty, Xiaodong Shen
Journal: Journal of Clinical Oncology (2012)

535 Background: Dysregulation of MET and VEGF signaling has been implicated in breast cancer development and progression, including tumor invasion and dissemination. Cabozantinib (cabo) is an oral, potent inhibitor of MET and VEGFR2. A RDT evaluated activity and safety in 9 tumor types, including MBC. Methods: Eligible patients (pts) were required to have progressive measurable disease per RECIST. Pts received cabo at 100 mg qd over a 12 wk Lead-in stage. Tumor response (mRECIST) was assessed q6 wks. Treatment ≥ wk 12 was based on response: pts with PR continued open-label cabo, pts with SD were randomized to cabo vs placebo, and pts with PD discontinued. Primary endpoint in the randomized discontinuation phase was progression-free survival (PFS). Results: Enrollment to this cohort is complete (n = 45); all pts are unblinded. Baseline characteristics: median age 56; invasive ductal 86%, invasive lobular 7%; ER+ 93%, HER2+ 18%, triple- 5%; visceral disease 91%; bone metastases 73%; median prior lines of therapy 3 (range 1-8), including 71% with prior anthracyclines. Median follow-up was 2.9 mos (range 0.1 -16). 21 pts (47%) completed Lead-in stage with only 9 randomized to continue cabo (n = 5) or placebo (n = 4). Median PFS from Study Day 1 was 4.1 mos. At wk 12, objective response rate was 14% and disease control rate 48%. Tumor regression was observed in 25/39 pts (64%) with ≥1 post-baseline tumor assessment. 4/10 pts evaluable by bone scan had partial resolution of bone lesions. Of 12 pts receiving narcotics for bone pain, 5 pts reported improved pain and 2 pts had decreased narcotics use, per investigator. 4/14 evaluable pts (29%) with bone metastases experienced ≥50% decline in serum NTx. Most common Grade 3/4 AEs were palmar-plantar erythrodyesthesia (13%) and fatigue (11%). One related Grade 5 AE of respiratory compromise was reported during the Lead-in stage. Conclusions: Cabo demonstrated a 14% rate of objective tumor regression in heavily pretreated MBC pts. Observed effects on bone scan and pain are consistent with those seen in other malignancies. The safety profile of cabo was comparable to that seen with other VEGFR TKIs.
RNA Sequencing Identifies Novel Translational Biomarkers of Kidney Fibrosis
Authors: Florin L. Craciun, Vanesa Bijol, Amrendra K. Ajay, Poornima Rao, Ramya K. Kumar, John Hutchinson, Oliver Hofmann, Nikita Joshi, James P. Luyendyk, Ulrike Kusebauch, Christopher L. Moss, Anand Srivastava, Jonathan Himmelfarb, Sushrut S. Waikar, Robert L. Moritz, Vishal S. Vaidya
Journal: Journal of the American Society of Nephrology (2015)

CKD is the gradual, asymptomatic loss of kidney function, but current tests only identify CKD when significant loss has already happened. Several potential biomarkers of CKD have been reported, but none have been approved for preclinical or clinical use. Using RNA sequencing in a mouse model of folic acid-induced nephropathy, we identified ten genes that track kidney fibrosis development, the common pathologic finding in patients with CKD. The gene expression of all ten candidates was confirmed to be significantly higher (approximately ten- to 150-fold) in three well established, mechanistically distinct mouse models of kidney fibrosis than in models of nonfibrotic AKI. Protein expression of these genes was also high in the folic acid model and in patients with biopsy-proven kidney fibrosis. mRNA expression of the ten genes increased with increasing severity of kidney fibrosis, decreased in response to therapeutic intervention, and increased only modestly (approximately two- to five-fold) with liver fibrosis in mice and humans, demonstrating specificity for kidney fibrosis. Using targeted selected reaction monitoring mass spectrometry, we detected three of the ten candidates in human urine: cadherin 11 (CDH11), macrophage mannose receptor C1 (MRC1), and phospholipid transfer protein (PLTP). Furthermore, urinary levels of each of these three proteins distinguished patients with CKD ( n =53) from healthy individuals ( n =53; P &lt;0.05). In summary, we report the identification of urinary CDH11, MRC1, and PLTP as novel noninvasive biomarkers of CKD.
A pseudopyloric channel created by repeated blind post-pyloric feeding tube placement
Authors: Kunal Karamchandani, John Levenick, Charles Dye, David Campbell
Journal: Endoscopy (2015)

A 58-year-old man with esophageal cancer underwent a transhiatal esophagectomy and presented to the surgical intensive care unit (SICU) with progressively worsening shortness of breath 14 days after his surgery. The patient was found to have a left empyema, possibly from an anastomotic leak, and underwent a left video-assisted thoracotomy (VATS) decortication and empyema drainage, and endoscopic placement of two tandem fully covered esophageal stents. While recovering in the SICU, the patient had multiple episodes of agitation that resulted in his pulling out his post-pyloric feeding tube. The tube was reinserted blindly at the bedside multiple times without any obvious difficulty or complications.
Pre- and post-bronchodilator spirometric values and the degree of reversibility in patients with COPD
Authors: M. Maden, M. Hind
Journal: European Respiratory Journal (2004)

From the authors: 

H. Fehrenbach is perfectly correct to point out that the assessment of our data is based only on the measurement of mean chord length (Lm) and lung volume estimations, whereas “a whole range of stereological tools is available for more detailed anaysis”. However, the results were so dramatic that we felt that there was no need for these further, rather esoteric analyses, which would …
Release of Active Peptidyl Arginine Deiminases by Neutrophils Can Explain Production of Extracellular Citrullinated Autoantigens in Rheumatoid Arthritis Synovial Fluid
Authors: Julia Spengler, Božo Lugonja, A. Jimmy Ytterberg, Roman A. Zubarev, Andrew J. Creese, Mark J. Pearson, Melissa M. Grant, Michael Milward, Karin Lundberg, Christopher D. Buckley, Andrew Filer, Karim Raza, Paul R. Cooper, Iain L. Chapple, Dagmar Scheel‐Toellner
Journal: Arthritis & Rheumatology (2015)

Objective In the majority of patients with rheumatoid arthritis (RA), antibodies specifically recognize citrullinated autoantigens that are generated by peptidylarginine deiminases (PADs). Neutrophils express high levels of PAD and accumulate in the synovial fluid (SF) of RA patients during disease flares. This study was undertaken to test the hypothesis that neutrophil cell death, induced by either NETosis (extrusion of genomic DNA–protein complexes known as neutrophil extracellular traps [NETs]) or necrosis, can contribute to production of autoantigens in the inflamed joint. Methods Extracellular DNA was quantified in the SF of patients with RA, patients with osteoarthritis (OA), and patients with psoriatic arthritis (PsA). Release of PAD from neutrophils was investigated by Western blotting, mass spectrometry, immunofluorescence staining, and PAD activity assays. PAD2 and PAD4 protein expression, as well as PAD enzymatic activity, were assessed in the SF of patients with RA and those with OA. Results Extracellular DNA was detected at significantly higher levels in RA SF than in OA SF ( P &lt; 0.001) or PsA SF ( P &lt; 0.05), and its expression levels correlated with neutrophil concentrations and PAD activity in RA SF. Necrotic neutrophils released less soluble extracellular DNA compared to NETotic cells in vitro ( P &lt; 0.05). Higher PAD activity was detected in RA SF than in OA SF ( P &lt; 0.05). The citrullinated proteins PAD2 and PAD4 were found attached to NETs and also freely diffused in the supernatant. PAD enzymatic activity was detected in supernatants of neutrophils undergoing either NETosis or necrosis. Conclusion Release of active PAD isoforms into the SF by neutrophil cell death is a plausible explanation for the generation of extracellular autoantigens in RA.
CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study
Authors: Raoul Herbrecht, David MacDonald, Florian Weissinger, Martin Wilhelm, Charles Holladay, Nam H. Dang, Peter Holman, Paul Cernohous, Jack Singer, Richard H. van der Jagt
Journal: Blood (2011)
Determination of glomerular size-selectivity in the normal rat with Ficoll.
Authors: J D Oliver, S Anderson, J L Troy, B M Brenner, W H Deen
Journal: Journal of the American Society of Nephrology (1992)

Diffusion studies in vitro indicate that Ficoll behaves more like an ideal spherical molecule than does dextran, suggesting that Ficoll would be a better probe of glomerular pore size than the commonly used dextran. To examine the differences between these macromolecules in vivo, the fractional clearances of tritiated Ficoll and dextran were measured over a wide range of molecular sizes (Stokes-Einstein radius, rs, from 19 to 65 A) in normal euvolemic Munich-Wistar rats. Whole-kidney and single-nephron hemodynamic conditions were characterized through a combination of clearance and micropuncture measurements. The fractional clearance, or sieving coefficient (theta), for dextran significantly exceeded that of Ficoll at all molecular sizes examined, theta for dextran being approximately 10 times that for Ficoll for rs greater than 30 A. Thus, the results with Ficoll imply a more size-restrictive barrier than do the results with dextran. The values of theta for Ficoll approximated previously reported values for uncharged globular proteins. Although theta for Ficoll at rs = 35 A was much smaller than the corresponding value for dextran, it was still approximately 30 times greater than typical values of the filtrate-to-plasma concentration ratio reported for serum albumin (a polyanion) in the rat, in agreement with the concept that glomerular charge-selectivity normally plays an important role in the prevention of albuminuria. Three membrane-pore models were compared in their ability to represent the dextran and Ficoll sieving data. A lognormal pore-size distribution in parallel with a nonselective "shunt" pathway was found to be more effective than either an isoporous membrane with a shunt or a purely lognormal distribution. On the basis of these laboratory results and computations, Ficoll may be preferred over dextran in future studies of glomerular size-selectivity.